バリシチニブは関節リウマチ患者の骨量と力学機能を改善 – 前向き介入BARE BONE 治験結果

The results from Simon, et al. show that baricitinib treatment correlates with improvements in bone stiffness. Further improvements were also observed at the end of Week 52, with an increase in estimated failure load and no measurable progression in bone erosion being reported.

These results come from the BARE-BONE trial, which is a prospective, single-arm, open-label, single-centre phase 4 study. Bone properties and synovial inflammation were assessed using CT scans and MRI at baseline, Week 24 and Week 52.